Sulfatides as anti-inflammatory compounds
US5486536A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Aug 15, 1994 |
| Grant date | Jan 23, 1996 |
| Priority date | — |
| Expiry date | Aug 15, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/7032
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Using in vitro adhesion of recombinant rat L-selectin-Ig or rat neutrophils, it has been demonstrated that these materials bind to sulfatide that has been present in solid phase on a plastic surface. The binding activity appears to have structural requirements, with the sulfate group being critically present in position 3 on the pyranose ring of galactose. When used in vivo, it has been demonstrated that sulfated glycolipids such as brain sulfatide and ganglioside, have significantly protective effects in two models of lung inflammation, the first systemic activation of complement and the second occurring after intrapulmonary deposition of immune complexes. Both inflammatory reactions are complement, neutrophil and selectin-dependent. The protective effects of these compounds are linked to their ability to prevent the recruitment of neutrophils into lung tissue. On the basis of these findings, it is demonstrated by sulfatides and related compounds have significant in vivo anti-inflammatory activities. These compounds thus represent a new class of anti-inflammatory agents.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.